Identification of circulating tumor cells with EML4‑ALK translocation using fluorescence inï¿½situ hybridization in advanced ALK‑positive patients with lung cancer

Kim, Young Hun; Hwang, Eun Ju; Lee, Hye Seon; Uh, Ji‐Hyun; Kim, Myoung Shin; Jeon, Byung Hee

doi:10.3892/ol.2018.8480

Cited by 2 publications

(1 citation statement)

References 35 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, label-free technologies, depending on size, density, and dielectrophoresis properties, isolate heterogeneous population of CTCs. There are other label-free technologies available for CTC detection, for instance, EPISPOT, which discriminates between viable and apoptotic CTCs using protein secretion [21], FISH-based assays [22,23], and metabolic approaches that measure the fluctuations in pH or lactate concentration in CTCs [24]. Label-free technologies are often limited by the throughput.…”

Section: Introductionmentioning

confidence: 99%

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients

Zeinali

Lee

Nadhan

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background: Circulating tumor cell (CTC) clusters are emerging as clinically significant harbingers of metastases in solid organ cancers. Prior to engaging these CTC clusters in animal models of metastases, it is imperative for technology to identify them with high sensitivity. These clusters often present heterogeneous surface markers and current methods for isolation of clusters may fall short. (2) Methods: We applied an inertial microfluidic Labyrinth device for high-throughput, biomarker-independent, size-based isolation of CTCs/CTC clusters from patients with metastatic non-small-cell lung cancer (NSCLC). (3) Results: Using Labyrinth, CTCs (PanCK+/DAPI+/CD45−) were isolated from patients (n = 25). Heterogeneous CTC populations, including CTCs expressing epithelial (EpCAM), mesenchymal (Vimentin) or both markers were detected. CTCs were isolated from 100% of patients (417 ± 1023 CTCs/mL). EpCAM− CTCs were significantly greater than EpCAM+ CTCs. Cell clusters of ≥2 CTCs were observed in 96% of patients—of which, 75% were EpCAM−. CTCs revealed identical genetic aberrations as the primary tumor for RET, ROS1, and ALK genes using fluorescence in situ hybridization (FISH) analysis. (4) Conclusions: The Labyrinth device recovered heterogeneous CTCs in 100% and CTC clusters in 96% of patients with metastatic NSCLC. The majority of recovered CTCs/clusters were EpCAM−, suggesting that these would have been missed using traditional antibody-based capture methods.

show abstract

Section: Introductionmentioning

confidence: 99%

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients

Zeinali

Lee

Nadhan

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia

Jiang

Wang

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Objective. The aim of this research was to create a new genetic signature of immune checkpoint-associated genes as a prognostic method for pediatric acute myeloid leukemia (AML). Methods. Transcriptome profiles and clinical follow-up details were obtained in Therapeutically Applicable Research to Generate Effective Treatments (TARGET), a database of pediatric tumors. Secondary data was collected from the Gene Expression Omnibus (GEO) to test the observations. In univariate Cox regression and multivariate Cox regression studies, the expression of immune checkpoint-related genes was studied. A three-mRNA signature was developed for predicting pediatric AML patient survival. Furthermore, the GEO cohort was used to confirm the reliability. A bioinformatics method was utilized to identify the diagnostic and prognostic value. Results. A three-gene (STAT1, BATF, EML4) signature was developed to identify patients into two danger categories depending on their OS. A multivariate regression study showed that the immune checkpoint-related signature (STAT1, BATF, EML4) was an independent indicator of pediatric AML. By immune cell subtypes analyses, the signature was correlated with multiple subtypes of immune cells. Conclusion. In summary, our three-gene signature can be a useful tool to predict the OS in AML patients.

show abstract

Identification of circulating tumor cells with EML4‑ALK translocation using fluorescence inï¿½situ hybridization in advanced ALK‑positive patients with lung cancer

Cited by 2 publications

References 35 publications

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients

An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia

Contact Info

Product

Resources

About